Volanesorsen for treating familial chylomicronaemia syndrome

that this introduced uncertainty into consideration of the clinical data, but concluded that it was acceptable for decision making. Generalisability of the trial population to clinical practice 4.5 Most of the patients in the company's clinical trials had a genetic diagnosis of FCS, in line with the marketing authorisation. The committee discussed whether the trial populations would represent people with FCS seen in the NHS. It noted that about 50% of patients in APPROACH lacked known functional mutations in the lipoprotein lipase gene. However, it understood that some patients with FCS may have unknown gene mutations that cannot currently be identified, and such patients may have entered the trial. However, because the marketing authorisation requires a genetic diagnosis of FCS, these patients would not be part of the NHS population potentially eligible for treatment with volanesorsen. The company explained that there is no clear correlation between types of gene mutation and disease prognosis. The committee agreed that, given this, it was reasonable to consider the trial population to be generalisable to clinical practice. High risk of pancreatitis in relation to TG levels 4.6 The marketing authorisation for volanesorsen stipulates that people must have a high risk of pancreatitis to be
